BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2024-02
167 industry Phase 2/3 trial readout(s) and 23 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2024-02 est. | P3 | Medlab Clinical | NCT04808531 NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers | Cancer Related Pain | unknown | 360 |
| 2024-02-01 est. | P1/P2 | Taiwan Leader Biotech Corp. | NCT02826837 LEAC-102 for Advanced Colorectal Cancer | Advanced Colorectal Cancer | unknown | 30 |
| 2024-02-01 est. | P2/P3 | Neuroplast | NCT03935724 Stem Cells in Spinal Cord Injury | Spinal Cord Injuries; Acute Spinal Cord Injury; Paraplegia, Spinal; Paraplegia; Traumatic | unknown | 16 |
| 2024-02-01 | P2 | Novartis Pharmaceuticals NVS | NCT04066244 Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients | Amyotrophic Lateral Sclerosis | terminated | 28 |
| 2024-02-01 | P2 | BeiGene | NCT04948697 A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC | Advanced Hepatocellular Carcinoma | completed | 94 |
| 2024-02-01 | P2/P3 | ContinueYou, LLC | NCT05227339 RAE (Realize, Analyze, Engage) | Substance Use Disorders; Treatment Adherence and Compliance | completed | 209 |
| 2024-02-01 est. | P2 | Zylorion Health | NCT05438758 Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study | Treatment Resistant Major Depressive Disorder | withdrawn | |
| 2024-02-01 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05481645 Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. | Advanced Endometrial Cancer; Sarcoma of Uterus | terminated | 71 |
| 2024-02-01 | P2 | Renovion, Inc. | NCT05495243 Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough | Non-cystic Fibrosis Bronchiectasis | completed | 40 |
| 2024-02-01 | P2 | Sanotize Research and Development corp. | NCT05877313 Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) | Verruca Plantaris | completed | 20 |
| 2024-02-02 | P1/P2 | GlaxoSmithKline | NCT04886154 A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults | Infections, Meningococcal | completed | 1440 |
| 2024-02-02 | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05011019 A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis | Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors | terminated | 22 |
| 2024-02-02 | P3 | Neurocrine UK Limited NBIX | NCT05063994 Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia | Congenital Adrenal Hyperplasia | completed | 55 |
| 2024-02-02 | P1/P2 | Theseus Pharmaceuticals | NCT05160168 A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Gastrointestinal Stromal Tumors (GIST); Neoplasms, Connective Tissue; Neoplasms, Connective and Soft | terminated | 32 |
| 2024-02-02 | P2 | ARS Pharmaceuticals, Inc. SPRY | NCT05363670 Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma | Asthma | completed | 18 |
| 2024-02-02 | P3 | Cara Therapeutics, Inc. | NCT05387707 Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With | Pruritus; Atopic Dermatitis | terminated | 287 |
| 2024-02-02 | P2 | MC2 Therapeutics | NCT05482698 The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial | Chronic Kidney Disease-associated Pruritus | completed | 111 |
| 2024-02-02 | P3 | GlaxoSmithKline | NCT05630833 A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis) | Urinary Tract Infections | completed | 380 |
| 2024-02-02 | P2 | Lallemand Health Solutions | NCT05766306 The Efficacy of a Probiotic Blend on Stress in Moderately Stressed Teens | Stress | completed | 30 |
| 2024-02-02 | P1/P2 | Nasus Pharma NSRX | NCT06205134 Comparative Bioavailability of Intranasal Epinephrine | Anaphylaxis; Anaphylactic Reaction | completed | 12 |
| 2024-02-02 est. | P2 | Hvivo | NCT06254820 Dose, Safety, and Pathogenicity of a New Influenza B Strain | Influenza B | unknown | 60 |
| 2024-02-03 est. | P3 | Bausch Health Americas, Inc. | NCT04151719 An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer | Pancreatic Cancer | withdrawn | |
| 2024-02-04 | P1/P2 | Suzhou Junjing BioSciences Co., Ltd. | NCT04993391 AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer | Lung Cancer | terminated | 32 |
| 2024-02-05 | P2 | Regeneron Pharmaceuticals REGN | NCT04698187 CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma | Melanoma; Advanced Melanoma; Metastatic Melanoma; Unresectable Melanoma | terminated | 44 |
| 2024-02-05 | P2 | Hansa Biopharma AB | NCT05049850 A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation | Kidney Transplantation in Highly Sensitized Patients | terminated | 3 |
| 2024-02-06 | P3 | AbbVie ABBV | NCT03725202 A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis | Giant Cell Arteritis (GCA) | completed | 429 |
| 2024-02-06 | P1/P2 | Numab Therapeutics AG | NCT04442126 A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Advanced Solid Tumor; Non-small Cell Lung Cancer; Colorectal Cancer; Squamous Cell Carcinoma; Ovaria | terminated | 52 |
| 2024-02-06 | P2 | Sanofi SNY | NCT05104892 Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma | Asthma | completed | 196 |
| 2024-02-06 | P2 | Denovo Biopharma LLC | NCT05113771 A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD | Treatment Resistant Depression | completed | 197 |
| 2024-02-06 | P3 | Pfizer PFE | NCT05371652 A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants | Acute Migraine | completed | 241 |
| 2024-02-06 est. | P3 | Neutec Ar-Ge San ve Tic A.Ş | NCT05890638 Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable Chronic | COPD | unknown | 74 |
| 2024-02-07 | P3 | Merck Sharp & Dohme LLC MRK | NCT03976323 Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339 | Carcinoma, Nonsquamous Non-small-cell Lung | completed | 1003 |
| 2024-02-07 | P3 | AstraZeneca AZN | NCT05056727 A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Ri | Renal Insufficiency, Chronic; Hyperkalemia | terminated | 1112 |
| 2024-02-07 | P3 | Samyang Biopharmaceuticals Corporation | NCT05207514 Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer | Breast Cancer | terminated | 26 |
| 2024-02-07 | P1/P2 | BioInvent International AB | NCT05555251 BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors | HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Metastatic Breast Cancer; M | terminated | 18 |
| 2024-02-07 | P2 | TriGemX Bio, Inc. | NCT06019559 A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833 | Obesity | completed | 155 |
| 2024-02-08 | P2 | Ionis Pharmaceuticals, Inc. IONS | NCT04014335 A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropa | Primary IgA Nephropathy | completed | 23 |
| 2024-02-08 | P3 | Estetra | NCT04209543 Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I) | Vasomotor Symptoms; Menopausal Symptoms | completed | 1570 |
| 2024-02-08 | P3 | AstraZeneca AZN | NCT04739761 A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer | Breast Cancer | active not recruiting | 506 |
| 2024-02-08 | P2 | Janssen Research & Development, LLC | NCT04836559 A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy | Focal Onset Seizures | completed | 110 |
| 2024-02-08 | P2 | Eirion Therapeutics Inc. | NCT04985916 ET-01 in Subjects With Lateral Canthal Lines, LCL-210 | Lateral Canthal Lines, LCL; Crow's Feet | completed | 280 |
| 2024-02-08 | P3 | Eli Lilly and Company LLY | NCT05169567 Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer | Breast Neoplasm; Neoplasm Metastasis | active not recruiting | 368 |
| 2024-02-08 | P2 | Kiniksa Pharmaceuticals, Ltd. KNSA | NCT05198310 Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Le | Arthritis, Rheumatoid | completed | 145 |
| 2024-02-08 | P2 | TBF Genie Tissulaire | NCT05250726 Use of a Treated, Devitalized and Sterile Meniscus Segment (MENISC-T) in the Treatment of Scaphotrapeziotrapezoid Osteoarthritis | Osteoarthritis Hand | completed | 14 |
| 2024-02-08 | P3 | Bristol-Myers Squibb BMY | NCT05297565 A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection | Melanoma | completed | 14 |
| 2024-02-09 | P2 | Spruce Biosciences SPRB | NCT04457336 A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH | Congenital Adrenal Hyperplasia | terminated | 96 |
| 2024-02-09 | P2 | GlaxoSmithKline | NCT05084508 A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to He | Chickenpox | completed | 800 |
| 2024-02-12 | P3 | AbbVie ABBV | NCT04435600 A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms | Psoriasis | completed | 139 |
| 2024-02-12 | P2 | COMPASS Pathways CMPS | NCT05312151 The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | Post Traumatic Stress Disorder | completed | 22 |
| 2024-02-12 | P2 | EyePoint Pharmaceuticals, Inc. EYPT | NCT05383209 Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR) | Nonproliferative Diabetic Retinopathy | completed | 77 |
| 2024-02-12 | P2 | Aphaia Pharma US LLC | NCT05803772 A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation in Subjects With a Pathological Oral Glucose Tolerance Test | PreDiabetes; Glucose Tolerance Impaired | completed | 31 |
| 2024-02-13 | P1/P2 | OBI Pharma, Inc | NCT03592264 A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | Solid Tumor; Pancreatic Adenocarcinoma | terminated | 68 |
| 2024-02-13 | P3 | AstraZeneca AZN | NCT05251909 Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) | Eosinophilic Gastritis; Eosinophilic Gastroenteritis | terminated | 12 |
| 2024-02-13 | P2/P3 | Annovis Bio Inc. ANVS | NCT05686044 A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD | Alzheimer Disease | completed | 351 |
| 2024-02-13 | P3 | Celltrion Pharm, Inc. | NCT07564726 Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol | Hypertension; Hypercholesterolemia | completed | 163 |
| 2024-02-14 | P1/P2 | BioMarin Pharmaceutical BMRN | NCT02576795 Gene Therapy Study in Severe Haemophilia A Patients (270-201) | Severe Haemophilia A | completed | 15 |
| 2024-02-14 | P2 | Bukwang Pharmaceutical | NCT04377945 Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components | Dyskinesias; Parkinson Disease | terminated | 41 |
| 2024-02-14 | P2 | Ascend Biopharmaceuticals Ltd AAWH | NCT04416516 Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor | Basal Cell Carcinoma; Basal Cell Nevus Syndrome | completed | 21 |
| 2024-02-14 | P1/P2 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | NCT05199337 Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis | Amyloidosis; AL Amyloidosis | completed | 18 |
| 2024-02-14 | P3 | Huons Co., Ltd. | NCT05743764 HU007 in Patients with Dry Eye Syndrome | Dry Eye Disease | completed | 328 |
| 2024-02-14 | P2 | Wuhan YZY Biopharma Co., Ltd. | NCT06266091 Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody | Malignant Ascites | completed | 115 |
| 2024-02-14 | P1/P2 | GlaxoSmithKline | NCT06655818 Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM | Relapsed/Refractory Multiple Myeloma | terminated | 4 |
| 2024-02-15 | P3 | Albireo, an Ipsen Company | NCT03659916 Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC | Progressive Familial Intrahepatic Cholestasis | completed | 116 |
| 2024-02-15 | P3 | GlaxoSmithKline | NCT04091451 Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age | Herpes Zoster | completed | 1430 |
| 2024-02-15 | P2/P3 | Laurent Pharmaceuticals Inc. | NCT04417257 Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults | COVID-19 Disease | terminated | 351 |
| 2024-02-15 | P2 | Anthos Therapeutics, Inc. | NCT04755283 Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation | Atrial Fibrillation (AF); Stroke | active not recruiting | 1287 |
| 2024-02-15 est. | P3 | Shanghai Henlius Biotech | NCT04806945 A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer | Cervical Cancer | withdrawn | |
| 2024-02-15 | P1/P2 | Celularity Incorporated CELU | NCT05207722 CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophagea | Metastatic HER2 Positive Gastroesophageal Junction Cancer | terminated | 1 |
| 2024-02-15 est. | P1/P2 | LaSanta S A S | NCT05272865 Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC | Nausea Post Chemotherapy; Vomiting; Cancer Pain; Cancer Related Pain; Neoplasms | unknown | 334 |
| 2024-02-15 | P3 | Eli Lilly and Company LLY | NCT05288166 A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormona | Prostatic Neoplasms; Neoplasm Metastasis; Urogenital Neoplasms; Physiological Effects of Drugs; Anti | active not recruiting | 925 |
| 2024-02-16 | P2 | DiaVacs, Inc. | NCT02354911 Autologous Immunoregulatory Dendritic Cells for Type 1 Diabetes Therapy | Type 1 Diabetes | withdrawn | |
| 2024-02-16 | P3 | Merck Sharp & Dohme LLC MRK | NCT03221426 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcino | Gastric Cancer; Gastroesophageal Junction Cancer | completed | 1007 |
| 2024-02-16 | P1/P2 | IGM Biosciences, Inc. | NCT04082936 A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | Non-Hodgkin Lymphoma; Follicular Lymphoma; DLBCL; Mantle Cell Lymphoma; Marginal Zone Lymphoma | terminated | 97 |
| 2024-02-16 | P3 | SK Life Science, Inc. | NCT04557085 Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS | Partial Seizure; Focal Seizure | completed | 519 |
| 2024-02-16 | P2 | Sanofi SNY | NCT04659603 Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors | Breast Cancer Metastatic; Pancreatic Carcinoma Metastatic | terminated | 50 |
| 2024-02-16 | P3 | Merck Sharp & Dohme LLC MRK | NCT04882241 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcino | Gastric Cancer; Gastroesophageal Junction Cancer | completed | 120 |
| 2024-02-16 | P3 | Kissei Pharmaceutical Co., Ltd. | NCT05445167 A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain | Uterine Fibroids (MeSH Heading: Leiomyoma) | completed | 89 |
| 2024-02-16 | P3 | Merck Sharp & Dohme LLC MRK | NCT05696080 Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) | Pneumococcal Infection | completed | 518 |
| 2024-02-18 | P2 | Calliditas Therapeutics Suisse SA | NCT05323656 A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) | Squamous Cell Carcinoma of Head and Neck | completed | 55 |
| 2024-02-19 | P2/P3 | Daehwa Pharmaceutical Co., Ltd. | NCT03315364 Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy | Recurrent or Metastatic Breast Cancer | active not recruiting | 549 |
| 2024-02-19 | P3 | Eli Lilly and Company LLY | NCT04527380 A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing | Juvenile Psoriatic Arthritis; Enthesitis Related Arthritis | active not recruiting | 101 |
| 2024-02-19 | P3 | GlaxoSmithKline | NCT05966090 A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults | Respiratory Syncytial Viruses; Respiratory Syncytial Virus Infections | completed | 530 |
| 2024-02-19 | P3 | Janssen Research & Development, LLC | NCT06134804 A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administrati | Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention | completed | 959 |
| 2024-02-20 | P1/P2 | TransThera Sciences (Nanjing), Inc. | NCT04742959 Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | Advanced Solid Tumor; Cholangiocarcinoma; HER2-negative Breast Cancer; Triple Negative Breast Cancer | completed | 203 |
| 2024-02-20 | P3 | Ultragenyx Pharmaceutical Inc RARE | NCT05139316 A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) | Glycogen Storage Disease Type IA | completed | 52 |
| 2024-02-20 | P2 | Endeavor Biomedicines, Inc. | NCT05199584 A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | Solid Tumors With PTCH1 Loss-of-function Mutations | completed | 20 |
| 2024-02-20 | P2 | Disc Medicine, Inc IRON | NCT05308472 Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP | Erythropoietic Protoporphyria | completed | 75 |
| 2024-02-20 | P2/P3 | Qilu Pharmaceutical Co., Ltd. | NCT05554913 Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia | Chemotherapy-induced Thrombocytopenia | completed | 63 |
| 2024-02-20 | P3 | Biosplice Therapeutics, Inc. | NCT05603754 Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis (STRIDES) | Knee Osteoarthritis | completed | 499 |
| 2024-02-20 | P3 | Otsuka Pharmaceutical Co., Ltd. | NCT05683340 A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia | Hyper-low-density Lipoprotein (LDL) Cholesterolemia | completed | 96 |
| 2024-02-20 | P2 | Allogene Therapeutics ALLO | NCT05714345 Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy | Relapsed/Refractory Large B Cell Lymphoma | terminated | 2 |
| 2024-02-20 | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT05795517 Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD) | Hypercholesterolemia | completed | 210 |
| 2024-02-20 | P1/P2 | Beijing Kanova Biopharmaceutical Co., LTD | NCT05991661 XKH001 Injection in Healthy Subjects | Asthma | completed | 24 |
| 2024-02-21 | P3 | Pharmacyclics LLC. | NCT02947347 Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma | Follicular Lymphoma | completed | 445 |
| 2024-02-21 | P3 | Biogen BIIB | NCT04089566 Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy | Muscular Atrophy, Spinal | completed | 145 |
| 2024-02-21 | P2 | LigaChem Biosciences, Inc. | NCT05225558 A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia | MRSA Bacteremia | terminated | 40 |
| 2024-02-21 | P2 | TBF Genie Tissulaire | NCT05302609 Evaluation of SclerFIX Graft in Scleral Thinning After Exeresis of Tumors of the Ocular Surface | Scleral Thinning | terminated | 17 |
| 2024-02-21 | P3 | PolarityTE | NCT05372809 Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs | Diabetic Foot | terminated | 42 |
| 2024-02-21 | P2 | ONL Therapeutics | NCT05730218 A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment | Rhegmatogenous Retinal Detachment - Macula Off | completed | 136 |
| 2024-02-21 | P2 | CSPC Ouyi Pharmaceutical Co., Ltd. | NCT05858047 An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque Psoriasis | Effects, Drug Side | completed | 93 |
| 2024-02-22 | P2 | Bristol-Myers Squibb BMY | NCT04572893 Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities | Primary Familial Dilated Cardiomyopathy | terminated | 41 |
| 2024-02-22 | P2 | BeiGene | NCT04716634 Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors | Advanced Solid Tumors | completed | 84 |
| 2024-02-22 | P3 | Intra-Cellular Therapies, Inc. | NCT04985942 Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Major Depressive Disorder | completed | 485 |
| 2024-02-22 | P3 | Xuanzhu Biopharmaceutical Co., Ltd. | NCT05077449 A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer | Advanced Breast Cancer | active not recruiting | 300 |
| 2024-02-22 | P2 | PT Bio Farma | NCT05727215 Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age | COVID-19 | completed | 150 |
| 2024-02-22 | P2 | Xeris Pharmaceuticals XERS | NCT05823012 Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism | Hypothyroidism | completed | 46 |
| 2024-02-22 | P2 | Skye Bioscience, Inc. SKYE | NCT06144918 Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure | Primary Open Angle Glaucoma; Ocular Hypertension | completed | 56 |
| 2024-02-23 | P3 | Incyte Corporation INCY | NCT04680052 A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients Wit | Follicular Lymphoma; Marginal Zone Lymphoma | active not recruiting | 654 |
| 2024-02-23 | P1/P2 | GlaxoSmithKline | NCT05496231 A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age | Cervical Intraepithelial Neoplasia | completed | 1080 |
| 2024-02-23 | P3 | LEO Pharma | NCT05919082 A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis | Stable Plaque Psoriasis | completed | 604 |
| 2024-02-23 | P2/P3 | Gilead Sciences GILD | NCT05996744 Study of Obeldesivir in Children and Adolescents With COVID-19 | COVID-19 | terminated | 3 |
| 2024-02-23 | P2 | MEDA Pharma GmbH & Co. KG | NCT06126952 Azelastine Allergen Chamber - Onset of Action Study | Seasonal Allergic Rhinitis | completed | 84 |
| 2024-02-24 | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT04183790 Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older | Cystic Fibrosis | completed | 64 |
| 2024-02-24 | P2 | Transposon Therapeutics, Inc. | NCT04993768 A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy | completed | 42 |
| 2024-02-26 | P2 | Epizyme, Inc. | NCT02601950 A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | Malignant Rhabdoid Tumors (MRT); Rhabdoid Tumors of the Kidney (RTK); Atypical Teratoid Rhabdoid Tum | completed | 267 |
| 2024-02-26 | P2 | OnQuality Pharmaceuticals (USA) LLC | NCT04088318 A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients | Hand-Foot Skin Reaction (HFSR) | unknown | 170 |
| 2024-02-26 | P2 | 4SC AG | NCT04393753 Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 | Merkel Cell Carcinoma | completed | 19 |
| 2024-02-26 | P2 | Pliant Therapeutics, Inc. PLRX | NCT04480840 Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC) | Primary Sclerosing Cholangitis | completed | 121 |
| 2024-02-26 | P3 | Asahi Kasei Therapeutics, AB | NCT04541043 Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE) | Primary IgA Nephropathy | completed | 119 |
| 2024-02-26 | P2 | BeiGene | NCT04643470 Zanubrutinib in Participants With Active Proliferative Lupus Nephritis | Lupus Nephritis | completed | 177 |
| 2024-02-26 | P2 | Bristol-Myers Squibb BMY | NCT04766892 A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT | Heart Failure With Preserved Ejection Fraction | completed | 30 |
| 2024-02-26 | P3 | Cara Therapeutics, Inc. | NCT05356403 CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus | Chronic Kidney Diseases; Pruritus | terminated | 105 |
| 2024-02-26 | P2 | BeiGene | NCT05461794 Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | terminated | 96 |
| 2024-02-26 | P3 | Daewoong Pharmaceutical Co. LTD. | NCT05505994 The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin | Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders; Metabolic Disease; Endoc | unknown | 340 |
| 2024-02-26 | P3 | Protox Inc. | NCT06124794 The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines | Glabellar Frown Lines | completed | 155 |
| 2024-02-27 | P2 | Sanaria Inc. | NCT03503058 Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria | Malaria | completed | 345 |
| 2024-02-27 | P3 | Takeda TAK | NCT03596866 A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer | ALK+ Advanced NSCLC | completed | 248 |
| 2024-02-27 | P2 | Hansa Biopharma AB | NCT03943589 A Study of Imlifidase in Patients With Guillain-Barré Syndrome | Guillain-Barré Syndrome (GBS) | completed | 30 |
| 2024-02-27 | P2 | Eli Lilly and Company LLY | NCT04640077 A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) | Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Cognitive Impairment | completed | 95 |
| 2024-02-27 | P2 | Dragonboat Biopharmaceutical Company Limited | NCT04718584 the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors | Bladder Cancer; Renal Carcinoma; Advanced Penile Carcinoma | completed | 27 |
| 2024-02-27 | P2 | Neuren Pharmaceuticals Limited | NCT05025332 An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001) | Pitt Hopkins Syndrome | completed | 28 |
| 2024-02-27 | P1/P2 | Alladapt Immunotherapeutics, Inc. | NCT05243719 Open-label Extension Study of ADP101 | Food Allergy | terminated | 45 |
| 2024-02-27 | P2 | Palobiofarma SL | NCT05262218 Therapeutic Effect of PBF-680 in Patients With COPD | COPD | completed | 174 |
| 2024-02-27 | P3 | Eli Lilly and Company LLY | NCT05462756 A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily | Type 2 Diabetes; Type 2 Diabetes Treated With Insulin | completed | 730 |
| 2024-02-27 | P2 | Pulmatrix Inc. PULM | NCT05667662 Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA | ABPA | terminated | 8 |
| 2024-02-27 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT05792410 A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer. | HER2 Low Advanced or Metastatic Breast Cancer | unknown | 300 |
| 2024-02-27 | P2 | Modern Biosciences Ltd MDRN | NCT05951296 A Study to Investigate Leramistat in Patients With IPF | Idiopathic Pulmonary Fibrosis | withdrawn | |
| 2024-02-27 | P2 | Viking Therapeutics, Inc. VKTX | NCT06068946 VK2735 for Weight Management Phase 2 | Weight Loss | completed | 176 |
| 2024-02-28 | P2/P3 | NeuroRx, Inc. | NCT03395392 NRX-101 for Bipolar Depression With Subacute Suicidal Ideation | Bipolar Depression; Suicidal Ideation and Behavior | completed | 74 |
| 2024-02-28 | P3 | Novartis Pharmaceuticals NVS | NCT04047472 Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration | completed | 397 |
| 2024-02-28 | P2 | Elevation Oncology | NCT04383210 Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | Locally Advanced Solid Tumor; Metastatic Solid Tumor; Pancreatic Cancer; Lung Cancer; Head and Neck | terminated | 54 |
| 2024-02-28 | P3 | Sanofi SNY | NCT04456673 Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation | Chronic Obstructive Pulmonary Disease | completed | 935 |
| 2024-02-28 est. | P2 | Bristol-Myers Squibb BMY | NCT04495010 Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivo | Melanoma | withdrawn | |
| 2024-02-28 | P2 | Hovid Berhad | NCT04658823 Efficacy and Safety of Tocotrienols in CADASIL | Cadasil | completed | 50 |
| 2024-02-28 | P2 | Colgate Palmolive CL | NCT04750902 A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 | Dental Caries | completed | 2025 |
| 2024-02-28 | P2 | Akeso | NCT04868708 A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer | Recurrent or Metastatic Cervical Cancer | completed | 50 |
| 2024-02-28 | P2 | TransThera Sciences (Nanjing), Inc. | NCT04919642 Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma | Cholangiocarcinoma; FGFR2 Fusion; FGFR2 Gene Mutation; FGFR1 Alteration; FGFR3 Alteration | completed | 55 |
| 2024-02-28 est. | P2 | National Vaccine and Serum Institute, China | NCT04941261 Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha) | Norovirus Infections; Norwalk Gastroenteritis | unknown | 1716 |
| 2024-02-28 | P3 | Aerie Pharmaceuticals | NCT05493111 A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512 | Dry Eye Disease | completed | 275 |
| 2024-02-28 | P2 | Pascoe Pharmazeutische Praeparate GmbH | NCT05561257 Vitamin C as add-on Therapy in Patients With Acute Herpes Zoster | Neuropathic Pain | terminated | 12 |
| 2024-02-28 | P2 | Zevra Therapeutics ZVRA | NCT05668754 Study of SDX in Patients With Idiopathic Hypersomnia (IH) | Idiopathic Hypersomnia | completed | 66 |
| 2024-02-28 est. | P1/P2 | DualityBio Inc. | NCT05785728 A Study of DB-1202 Monotherapy in Advanced Solid Tumors | Advanced Solid Tumor | unknown | 150 |
| 2024-02-28 | P2 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT05936268 Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare | Acute Gout; Gout Flare | completed | 106 |
| 2024-02-29 | P1/P2 | Celgene | NCT01997840 ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma | Multiple Myeloma | terminated | 103 |
| 2024-02-29 | P3 | Denovo Biopharma LLC | NCT03776071 A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic | Glioblastoma | completed | 260 |
| 2024-02-29 | P3 | Janssen Pharmaceutical K.K. | NCT04397263 A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | Crohns Disease | completed | 38 |
| 2024-02-29 | P2 | Hutchison Medipharma Limited | NCT04849351 Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma | Marginal Zone Lymphoma; Follicular Lymphoma | completed | 178 |
| 2024-02-29 | P1/P2 | Asklepion Pharmaceuticals, LLC | NCT04852172 L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC) | Acute Vaso Occlusive Crisis (VOC) | terminated | 30 |
| 2024-02-29 | P3 | Organon and Co OGN | NCT05142774 Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis | Atopic Dermatitis | completed | 728 |
| 2024-02-29 | P2 | Kind Pharmaceuticals LLC | NCT05265325 A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis | Renal Anemia | completed | 175 |
| 2024-02-29 | P3 | Cingulate Therapeutics CING | NCT05286762 Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301 | ADHD; Attention Deficit Hyperactivity Disorder; ADHD - Combined Type; Attention Deficit Hyperactivit | completed | 103 |
| 2024-02-29 | P3 | Cara Therapeutics, Inc. | NCT05342623 A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus | Chronic Kidney Diseases; Pruritus | terminated | 286 |
| 2024-02-29 | P2 | Supernus Pharmaceuticals, Inc. SUPN | NCT05358821 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease | Huntington Disease | completed | 69 |
| 2024-02-29 | P2 | ARS Pharmaceuticals, Inc. SPRY | NCT05496465 Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares | Urticaria | completed | 21 |
| 2024-02-29 | P1/P2 | Dizal Pharmaceuticals | NCT05844956 A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) | Lymphoma, Non-Hodgkin | completed | 17 |
| 2024-02-29 | P2 | AlgoTherapeutix | NCT05917912 EASE (Efficacy of ATX01 Study in Erythromelalgia) | Erythromelalgia | completed | 14 |
| 2024-02-29 est. | P2 | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | NCT06170840 A Study of QY101 Ointment in Subjects With Plaque Psoriasis | Psoriasis | unknown | 160 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.